17 studies found for:    Tesamorelin OR Egrifta[TREATMENT] AND HIV [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Tesamorelin Effects on Liver Fat and Histology in HIV
Conditions: Human Immunodeficiency Virus (HIV);   Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: tesamorelin;   Drug: Placebo
2 Completed
Has Results
TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy
Conditions: Lipodystrophy;   HIV Infections
Interventions: Drug: Tesamorelin;   Drug: Placebo for Tesamorelin
3 Completed
Has Results
Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV;   HIV Lipodystrophy
Interventions: Drug: tesamorelin;   Drug: placebo
4 Completed Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
Condition: HIV
Intervention: Drug: Tesamorelin
5 Suspended Egrifta Replacement and Sleep Disordered Breathing
Condition: Lipodystrophy
Intervention: Drug: Tesamorelin (Egrifta)
6 Recruiting Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Condition: HIV
Intervention: Drug: Tesamorelin for injection
7 Not yet recruiting Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
Condition: Mild Cognitive Impairment
Interventions: Drug: Tesamorelin;   Drug: Placebo
8 Recruiting Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Conditions: Diabetic Retinopathy;   HIV
Interventions: Drug: Tesamorelin;   Drug: Placebo-Control
9 Terminated
Has Results
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Tesamorelin
10 Completed TH9507 in Patients With HIV-Associated Lipodystrophy
Conditions: HIV Infections;   Lipodystrophy
Intervention: Drug: TH9507
11 Completed
Has Results
Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men
Condition: Healthy Volunteers
Intervention: Drug: Growth Hormone Releasing Hormone (Tesamorelin)
12 Completed Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
Condition: Type 2 Diabetes
Intervention: Drug: TH9507
13 Withdrawn Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
Condition: Abdominal Obesity
Interventions: Drug: Tesamorelin;   Drug: Placebo
14 Recruiting The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
Condition: Mild Cognitive Impairment
Intervention: Drug: Growth Hormone Releasing Hormone (GHRH)
15 Completed
Has Results
Effects of Short-term Growth Hormone in HIV-infected Patients
Condition: HIV Lipodystrophy
Interventions: Drug: Growth hormone;   Drug: Growth Hormone Releasing Hormone
16 Completed
Has Results
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Conditions: Abdominal Obesity;   Growth Hormone Deficiency
Interventions: Drug: Growth hormone releasing hormone (GHRH) 1-44;   Drug: Placebo
17 Completed SMART: Somatotrophics, Memory, and Aging Research Trial
Conditions: Aging;   Mild Cognitive Impairment
Intervention: Drug: TH9507 human growth hormone releasing hormone (GHRH)

Indicates status has not been verified in more than two years